Trial Profile
A Non-Interventional Phase IV Survey to Assess the Antiviral Effectiveness of PegIntron [Peginterferon-alfa-2b] and Rebetol [ribavirin] Treatment According to the Stage of Liver Fibrosis in Previously Untreated Patients With Genotype 1/4/5/6 Chronic Hepatitis C (CHC) (PRACTICE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PRACTICE
- Sponsors Merck Sharp & Dohme Corp.
- 16 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 16 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Aug 2009 Planned end date changed from 1 Sep 2010 to 1 Oct 2009 as reported by ClinicalTrials.gov.